国家卫生研究院加速COVID-19治疗干预和疫苗倡议启动COVID-19凝血治疗的适应性临床试验(美國美中報道)

国家卫生研究院(NIH)加速COVID-19治疗干预和疫苗(ACTIV-4)倡议启动COVID-19凝血治疗的适应性临床试验。大多数死于COVID-19的患者都出现了血栓。血液稀释剂可以防止血细胞变成血块或相互粘连。但医生不知道治疗COVID-19哪些血液稀释剂是最好用的或什么剂量是最有效的。国家卫生研究院将对3组被诊断为COVID-19的成年人进行不同剂量的血液稀释剂评估。

该实验将在世界各地100多个地点进行,并将提供有助于指导对COVID-19病人护理的关键性见解,尤其是那些患有危及生命的血栓的病人。

详情请见:

https://www.nih.gov/news-events/news-releases/nih-activ-initiative-launches-adaptive-clinical-trials-blood-clotting-treatments-covid-19

The U.S. National Institutes of Health (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines(ACTIV-4)initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19. The majority of patients who have died from COVID-19 developed blood clots. Blood thinners keep blood cells from turning into clumps or sticking to each other. But doctors don’t know which ones are best to use or what dose is most effective at treating COVID-19. NIH will evaluate varying doses of blood thinners with 3 groups of adults diagnosed with COVID-19.

The trials will be conducted at more than 100 sites around the world and will provide critical insights that could help guide the care of patients with COVID-19, particularly those who suffer from life-threatening blood clots.

More info:

https://www.nih.gov/news-events/news-releases/nih-activ-initiative-launches-adaptive-clinical-trials-blood-clotting-treatments-covid-19(美国驻华大使馆)

分享: